AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Long-Term Investments came in at $65.3 million in Q1 2026, down 19.93% YoY from $81.6 million in Q1 2025, and up 4.36% on a QoQ basis from $62.6 million in Q4 2025.
AbCellera Biologics (ABCL) Long-Term Investments (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Long-Term Investments data on file, last reported at $65.3 million in Q1 2026.
- Quarterly Long-Term Investments fell 19.93% year-over-year to $65.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.3 million (down 19.93% YoY) and the FY2025 annual result came in at $62.6 million, down 23.96% from the prior year.
- Long-Term Investments climbed to $65.3 million in Q1 2026, from $62.6 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $93.3 million in Q3 2025 to a low of $57.6 million in Q1 2023.
- A 5-year average of $71.5 million and a median of $66.7 million in 2022 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2022 — Long-Term Investments jumped 82.94% — and 2025, when it dropped 23.96%.
- Tracing ABCL's Long-Term Investments over 5 years: stood at $72.5 million in 2022, then dropped by 9.08% to $65.9 million in 2023, then grew by 24.81% to $82.3 million in 2024, then slipped by 23.96% to $62.6 million in 2025, then grew by 4.36% to $65.3 million in 2026.
- The last three Long-Term Investments figures came in at $65.3 million (Q1 2026), $62.6 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 65.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.23 Mn |
| Mar 31, 2026 | 65.31 Mn |
| Dec 31, 2025 | 62.58 Mn |
| Sep 30, 2025 | 93.30 Mn |
| Jun 30, 2025 | 90.37 Mn |
| Mar 31, 2025 | 81.57 Mn |
| Dec 31, 2024 | 82.30 Mn |
| Sep 30, 2024 | 84.08 Mn |
| Jun 30, 2024 | 76.06 Mn |
| Mar 31, 2024 | 71.59 Mn |
| Dec 31, 2023 | 65.94 Mn |
| Sep 30, 2023 | 62.89 Mn |
| Jun 30, 2023 | 58.79 Mn |
| Mar 31, 2023 | 57.58 Mn |
| Dec 31, 2022 | 72.52 Mn |
| Sep 30, 2022 | 66.72 Mn |
| Jun 30, 2022 | 65.82 Mn |
| Mar 31, 2022 | 58.88 Mn |
| Dec 31, 2021 | 50.31 Mn |
| Sep 30, 2021 | 47.51 Mn |